ARTICLE | Deals
Dynavax deal gives drug delivery play TriSalus its first therapeutic candidate
August 4, 2020 12:36 AM UTC
Monday’s deal with Dynavax marks TriSalus’ pivot into therapeutics development.
TriSalus Life Sciences gained exclusive, worldwide rights to SD-101, a TLR9 agonist, from Dynavax Technologies Corp. (NASDAQ:DVAX). TriSalus will pay Dynavax $5 million up front and $4 million on Dec. 30 to cover R&D expenses, and Dynavax is eligible for up to $250 million in milestones, plus low double-digit royalties. ...
BCIQ Company Profiles
BCIQ Target Profiles